[Form 4] Quest Diagnostics Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Insider Trade Summary
Net Seller: 10,479 shares ($1,759,931)
Net Sell
9 txns
Insider
KUPPUSAMY KARTHIK
Role
SVP, Clinical Solutions
Sold
10,479 shs ($1.76M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,210 | $170.00 | $376K |
| Exercise | Non-Qualifed Stock Option (right to buy) | 3,045 | $86.63 | $264K |
| Exercise | Non-Qualifed Stock Option (right to buy) | 5,224 | $112.17 | $586K |
| Exercise | Common Stock | 3,045 | $86.63 | $264K |
| Sale | Common Stock | 3,045 | $167.40 | $510K |
| Exercise | Common Stock | 5,224 | $112.17 | $586K |
| Sale | Common Stock | 5,224 | $167.40 | $874K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 8,450 shares (Direct);
Non-Qualifed Stock Option (right to buy) — 0 shares (Direct);
Common Stock — 358 shares (Indirect, By Trust)
Footnotes (1)
- This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022. The options vested in three annual installments beginning with the first on February 18, 2021, the second on February 18, 2022 and the final on February 18, 2023.
